No Data
Jefferies Maintains Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Raises Target Price to $27
Centessa Sleep Disorder Drug Sales Could Eventually Top $2.5B -- Market Talk
Centessa Pharmaceuticals' ORX750: Promising Phase I Results and Market Potential Justify Buy Rating
Centessa Pharmaceuticals: Promising OX2R Agonists for Unmet Narcolepsy Needs With Market Expansion Potential
Centessa Pharmaceuticals | 10-K: FY2024 Annual Report
Centessa Pharmaceuticals | 8-K: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
